OYC骨代謝関連製品掲載論文（共同研究を含む）
Recombinant Human sRANKLCat. No. 47187000
論文
Kawakami M, Yasuda H, Nishida D, Katakura A, Mizoguchi T. Development of a method for theidentification of receptor activator of nuclear factor-κB + populations in vivo., J Oral Biosci, 63:
45-51, 2021
Yasuda H. Discovery of the RANKL/RANK/OPG system. J Bone Miner Metab. 39, 2-11, 2021
Takakura N, Matsuda M, Khan M, Hiura F, Aoki K, Hirohashi Y, Mori K, Yasuda H, Hirata M, Kitamura C,
Jimi E. A novel inhibitor of NF-κB-inducing kinase prevents bone loss by inhibiting osteoclastic
bone resorption in ovariectomized mice. Bone. 2020 135:115316.
Kobayakawa M, Matsubara T, Mizokami A, Hiura F, Takakura N, Kokabu S, Matsuda M, Yasuda H,
Nakamura I, Takei Y, Honda H, Hosokawa R, Jimi E. Kif1c regulates osteoclastic bone resorption as adownstream molecule of p130Cas. Cell Biochem Funct. 2020 38:300-308.
Touyama K, Khan M, Aoki K, Matsuda M, Hiura F, Takakura N, Matsubara T, Harada Y, Hirohashi Y,
Tamura Y, Gao J, Mori K, Kokabu S, Yasuda H, Fujita Y, Watanabe K, Takahashi Y, Maki K, Jimi E. Bif1/Endophilin B1/SH3GLB1 regulates bone homeostasis. J Cell Biochem. 2019 120:18793-18804.
Tsukasaki M, Hamada K, Okamoto K, Nagashima K, Terashima A, Komatsu N, Win SJ, Okamura T, Nitta
T, Yasuda H, Penninger JM, Takayanagi H. LOX Fails to Substitute for RANKL in Osteoclastogenesis.
J Bone Miner Res. 2017; 32: 434-439.
Omata Y, Yasui T, Hirose J, Izawa N, Imai Y, Matsumoto T, Masuda H, Tokuyama N, Nakamura S,
Tsutsumi S, Yasuda H, Okamoto K, Takayanagi H, Hikita A, Imamura T, Matsuo K, Saito T, Kadono Y,
Aburatani H, Tanaka S. Genomewide comprehensive analysis reveals critical cooperation between
Smad and c-Fos in RANKL-induced osteoclastogenesis. J Bone Miner Res. 30: 869-877, 2015
Enoki Y, Sato T, Tanaka S, Iwata T, Usui M, Takeda S, Kokabu S, Matsumoto M, Okubo M, Nakashima
K, Yamato M, Okano T, Fukuda T, Chida D, Imai Y, Yasuda H, Nishihara T, Akita M, Oda H, Okazaki Y,
Suda T, Yoda T. Netrin-4 derived from murine vascular endothelial cells inhibits osteoclastdifferentiation in vitro and prevents bone loss in vivo. FEBS Lett. 588: 2262-2269, 2014
Kuchimaru T, Hoshino T, Aikawa T, Yasuda H, Kobayashi T, Kadonosono T, Kizaka-Kondoh S. Bone
resorption facilitates osteoblastic bone metastatic colonization by cooperation of insulin-likegrowth factor and hypoxia. Cancer Sci. 105: 553-559, 2014
Taniguchi R, Fukushima H, Osawa K, Maruyama T, Yasuda H, Weih F, Doi T, Maki K, Jimi E. RelBinduced expression of Cot, an MAP3K family member, rescues RANKL-induced osteoclastogenesis
in alymphoplasia mice by promoting NF-κB2 processing by IKKα. J Biol Chem. 289: 7349-7361,
2014
Yasuda H. RANKL, a necessary chance for clinical application to osteoporosis and cancer-relatedbone diseases. World J Orthop. 4: 207-217, 2013
Nagai Y, Osawa K, Fukushima H, Tamura Y, Aoki K, Ohya K, Yasuda H, Hikiji H, Takahashi M, Seta Y,
Seo S, Kurokawa M, Kato S, Honda H, Nakamura I, Maki K, Jimi E. p130Cas, Crk‐AssociatedSubstrate, Plays Important Roles in Osteoclastic Bone Resorption 2013, 28, 2449-2462
Nakamura H, Aoki K, Masuda W, Alles N, Nagano K, Fukushima H, Osawa K, Yasuda H, Nakamura I,
Mikuni-Takagaki Y, Ohya K, Maki K, Jimi E. Disruption of NF-κB1 prevents bone loss caused bymechanical unloading. J Bone Miner Res. 28, 1457-1467, 2013
Kikuta J, Wada Y, Kowada T, Wang Z, Sun-Wada GH, Nishiyama I, Mizukami S, Maiya N, Yasuda H,
Kumanogoh A, Kikuchi K, Germain RN, Ishii M. Dynamic visualization of RANKL and Th17-mediatedosteoclast function. J Clin Invest. 123: 866-873, 2013
Kotani M, Kikuta J, Klauschen F, Chino T, Kobayashi Y, Yasuda H, Tamai K, Miyawaki A, Kanagawa O,
Tomura M, Ishii M. Systemic circulation and bone recruitment of osteoclast precursors tracked byusing fluorescent imaging techniques. J Immunol. 190: 605-612. 2013

Ver.2021

Hayashi SI, Murata A, Okuyama K, Shimoda Y, Hikosaka M, Yasuda H, Yoshino M. Stochastic
differentiation into an osteoclast lineage from cloned macrophage-like cells. Biochem Biophys Res
Commun 428: 303–308, 2012
Nakamichi Y, Mizoguchi T, Arai A, Kobayashi Y, Sato M, Penninger JM, Yasuda H, Kato S, DeLuca HF,
Suda T, Udagawa N, Takahashi N. Spleen serves as a reservoir of osteoclast precursors throughvitamin D-induced IL-34 expression in osteopetrotic op/op mice. Proc Natl Acad Sci U S A.,
109:10006-10011, 2012
Arai A, Mizoguchi T, Harada S, Kobayashi Y, Nakamichi Y, Yasuda H, Penninger JM, Yamada K,
Udagawa N, Takahashi N. Fos plays an essential role in the upregulation of RANK expression in
osteoclast precursors within the bone microenvironment. J Cell Sci., 125: 2910-2917, 2012
Youn MY, Yokoyama A, Fujiyama-Nakamura S, Ohtake F, Minehata KI, Yasuda H, Suzuki T, Kato S,
Imai Y. JMJD5, a JmjC-domain-containing protein, negatively regulates osteoclastogenesis throughfacilitating NFATc1 protein degradation., J Biol Chem., 287: 12994-13004, 2012
Harada, S, Mizoguchi T, Kobayashi Y, Nakamichi Y, Takeda S, Sakai S, Takahashi F, Saito H, Yasuda
H, Udagawa N, Suda T, Takahashi N. Daily administration of eldecalcitol (ED-71), an active vitamin D
analog, increases bone mineral density by suppressing RANKL expression in mouse trabecularbone., J Bone Miner Res. 27: 461-473, 2012
Kinugawa S, Koide M, Kobayashi Y, Mizoguchi T, Ninomiya T, Muto A, Kawahara I, Nakamura M,
Yasuda H, Takahashi N, Udagawa N. Tetracyclines convert the osteoclastic-differentiation pathwayof progenitor cells to produce dendritic cell-like cells., J Immunol., 188: 1772-1781, 2012
Yasui T, Kadono Y, Nakamura M, Oshima Y, Matsumoto T, Masuda H, Hirose J, Omata Y, Yasuda H,
Imamura T, Nakamura K, Tanaka S.: Regulation of RANKL-induced osteoclastogenesis by TGF-β
through molecular interaction between Smad3 and TRAF6., J Bone Miner Res., 26: 1447-456, 2011
Hashiguchi D, Fukushima H, Nakamura M, Morikawa K, Yasuda H, Udagawa N, Maki K, Jimi E.: Mineral
trioxide aggregate solution inhibits osteoclast differentiation through the maintenance ofosteoprotegerin expression in osteoblasts., J Biomed Mater Res A. 96: 358-364, 2011
Maruyama T, Fukushima H, Nakao K, Shin M, Yasuda H, Weih F, Doi T, Aoki K, Alles N, Ohya K,
Hosokawa R, Jimi E.: Processing of the NF-kappaB2 Precursor, p100, to p52 is Critical for RANKLInduced Osteoclast Differentiation., J Bone Miner Res. 25: 1058-1067, 2010
Soysa NS, Alles N, Weih D, Lovas A, Mian AH, Shimokawa H, Yasuda H, Weih F, Jimi E, Ohya K, Aoki K.:
The Pivotal Role of the Alternative NF-kappaB Pathway in Maintenance of Basal Bone Homeostasis
and Osteoclastogenesis., J Bone Miner Res. 25: 809-818, 2010
Takada I, Tsuji N,1 Youn, M-Y, Fujiyama S, Okada Maiko, Imai1Y, Kondo S., Kitakawa H, Yasuda H,
and Kato S: Purification and identification of estrogen receptor alpha co-regulators in osteoclasts,
Ann. N.Y. Acad. Sci., 1192: 201–207, 2010
Youn, M-Y, Takada I, Imai Y, Yasuda H, and Kato S,: Transcriptionally active nuclei are selective inmature multinucleated osteoclasts, Genes to Cells, 15: 1025–1035, 2010
Koide M, Kinugawa S, Ninomiya T, Mizoguchi T, Yamashita T, Maeda K, Yasuda H, Kobayashi Y,
Nakamura H, Takahashi N, Udagawa N.: Diphenylhydantoin inhibits osteoclast differentiation andfunction through suppression of NFATc1 signaling., J Bone Miner Res., 24: 1469-1480, 2009
Tomimori Y, Mori K, Koide M, Nakamichi Y, Ninomiya T, Udagawa N, Yasuda H: Evaluation ofpharmaceuticals with a novel 50-hour animal model of bone loss., J Bone Miner Res., 24: 11941205, 2009
Shinohara M, Koga T, Okamoto K, Sakaguchi S, Arai K, Yasuda H, Takai T, Kodama T, Morio T, Geha
RS, Kitamura D, Kurosaki T, Ellmeier W, Takayanagi H.: Tyrosine kinases Btk and Tec regulate
osteoclast differentiation by linking RANK and ITAM signals., Cell, 132: 794-806, 2008
Maruyama K, Takada Y, Ray N, Kishimoto Y, Penninger JM, Yasuda H, Matsuo K.: Receptor activatorof NF-kappa B ligand and osteoprotegerin regulate proinflammatory cytokine production in mice., J
Immunol., 177: 3799-3805, 2006

Ver.2021

GST-RANKL-biotin
Cat. No. 47027000
論文
Kawakami M, Yasuda H, Nishida D, Katakura A, Mizoguchi T. Development of a method for theidentification of receptor activator of nuclear factor-κB + populations in vivo., J Oral Biosci, 63: 4551, 2021
Asano T, Okamoto K, Nakai Y, Tsutsumi M, Muro R, Suematsu A, Hashimoto K, Okamura T, Ehata S,
Nitta T, Takayanagi H, Soluble RANKL is physiologically dispensable but accelerates tumour
metastasis to bone. Nat Metab. 1: 868-875, 2019Charles JF, Hsu L-Y, Niemi EC, Weiss A, Aliprantis AO, Nakamura MC, Inflammatory arthritis increases
mouse osteoclast precursors with myeloid suppressor function., J Clin Invest, 122: 4592-4605,
2012

Anti-Mouse RANKL Monoclonal Antibody (OYC1)
Cat. No. 47104001
論文
3

Mori T, Horibe K, Masanori Koide , Uehara S, Yamamoto Y, Kato S, Yasuda H, Takahashi N, Udagawa
N, Nakamichi Y. The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the
Proresorptive Activity of 1α,25(OH)2D3 In Vivo. Endocrinology. 2020 Nov 1;161(11):bqaa178. doi:
10.1210/endocr/bqaa178.
Koide M, Yamashita T, Murakami K, Uehara S, Nakamura K, Nakamura M, Matsushita M, Ara T, Yasuda
H, Penninger JM, Takahashi N, Udagawa N, Kobayashi Y. Sclerostin expression in trabecular bone isdownregulated by osteoclasts. Sci Rep. 2020 Aug 13;10(1):13751. doi: 10.1038/s41598-02070817-1.
Hayano H, Kuroshima S, Sasaki M, Tamaki S, Inoue M, Ishisaki A, Sawase T.Hayano H, et al. Distinct
immunopathology in the early stages between different antiresorptives-related osteonecrosis of
the jaw-like lesions in mice. Bone. 2020 Jun; 135:115308. doi: 10.1016/j.bone.2020.115308. Epub2020 Mar 3. Bone. 2020. PMID: 32142911
Omiya T, Hirose J, Hasegawa T, Amizuka N, Omata Y, Izawa N, Yasuda H, Kadono Y, Matsumoto M,
Nakamura M, Miyamoto T, Tanaka S. The effect of switching from teriparatide to anti-RANKL
antibody on cancellous and cortical bone in ovariectomized mice. Bone. 2018 Feb;107:18-26
Okamatsu N, Sakai N, Karakawa A, Kouyama N, Sato Y, Inagaki K, Kiuchi Y, Oguchi K, Negishi-Koga T,
Takami M. Biological effects of anti-RANKL antibody administration in pregnant mice and theirnewborns. Biochem Biophys Res Commun. 2017 Sep 23;491(3):614-621.
Koide M, Kobayashi Y, Yamashita T, Uehara S, Nakamura M, Hiraoka BY, Ozaki Y, Iimura T, Yasuda H,
Takahashi N, Udagawa N. Bone Formation Is Coupled to Resorption Via Suppression of Sclerostin
Expression by Osteoclasts. J Bone Miner Res. 2017 May 24. doi: 10.1002/jbmr.3175. [Epub aheadof print]
RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nolan E,
Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L, Lok SW, Mann GB; Kathleen Cuningham
Foundation Consortium for Research into Familial Breast Cancer (kConFab)., Rohrbach K, Huang LY,
Soriano R, Smyth GK, Dougall WC, Visvader JE, Lindeman GJ. Nat Med. 2016 Aug;22(8):933-939.
Akiyama N, Takizawa N, Miyauchi M, Yanai H, Tateishi R, Shinzawa M, Yoshinaga R, Kurihara M,
Demizu Y, Yasuda H, Yagi S, Wu G, Matsumoto M, Sakamoto R, Yoshida N, Penninger JM, Kobayashi
Y, Inoue J, Akiyama T. Identification of embryonic precursor cells that differentiate into thymic
epithelial cells expressing autoimmune regulator. J Exp Med. 2016 213: 1441-1458.
Kuroshima, S, Zeina Al-Salihi Z,.Yamashita. Mouse anti-RANKL antibody delays oral wound healing
and increases TRAP-positive mononuclear cells in bone marrow. J Clin Oral Invest 20:727-736,
2016

Ver.2021

Kuroda Y, Maruyama K, Fujii H, Sugawara I, Ko SB, Yasuda H, Matsui H, Matsuo K. Osteoprotegerin
Regulates Pancreatic β-Cell Homeostasis upon Microbial Invasion. PLoS One. 11(1):e0146544,
2016
Tohyama R, Kayamori K, Sato K, Hamagaki M, Sakamoto K, Yasuda H, Yamaguchi A. Establishment ofa xenograft model to explore the mechanism of bone destruction by human oral cancers and its
application to analysis of role of RANKL. J Oral Pathol Med. doi: 10.1111/jop.12376, 2015 (hRANKL中和抗体も使用)Tokuyama N, Hirose J, Omata Y, Yasui T, Izawa N, Matsumoto T, Masuda H, Ohmiya T, Yasuda H,
Saito T, Kadono Y, Tanaka S. Individual and combining effects of anti-RANKL monoclonal antibody
and teriparatide in ovariectomized mice Bone Reports 2015, 2: 1–7
Akiyama T, Miyamoto Y, Yoshimura K, Yamada A, Takami M, Suzawa T, Hoshino M, Imamura T,
Akiyama C, Yasuhara R, Mishima K, Maruyama T, Kohda C, Tanaka K, Potempa J, Yasuda H, Baba K,
Kamijo R. Porphyromonas gingivalis-derived lysine gingipain enhances osteoclast differentiationinduced by tumor necrosis factor-α and interleukin-1β but suppresses that by interleukin-17A:
importance of proteolytic degradation of osteoprotegerin by lysine gingipain. J Biol Chem. 2014 :
289:15621-15630.
Funato S, Matsunaga A, Oh K, Miyamoto Y, Yoshimura K, Tanaka J, Suzuki D, Uyama R, Suzuki H,
Mishima K, Nakamura M, Namiki O, Baba K, Inagaki K, Kamijo R. Effects of antibody to receptor
activator of nuclear factor κ-B ligand on inflammation and cartilage degradation in collagenantibody-induced arthritis in mice. J Negat Results Biomed. 2014 Dec 12;13:18. doi:
10.1186/s12952-014-0018-0.
Yasuda H. RANKL, a necessary chance for clinical application to osteoporosis and cancer-relatedbone diseases. World J Orthop. 4: 207-217, 2013
Sato K, Lee JW, Sakamoto K, Iimura T, Kayamori K, Yasuda H, Shindoh M, Ito M, Omura K, Yamaguchi
A. RANKL Synthesized by Both Stromal Cells and Cancer Cells Plays a Crucial Role in Osteoclastic
Bone Resorption Induced by Oral Cancer. Am J Pathol. 182, 1890-1899, 2013 (hRANKL中和抗体も使用)
Kikuta J, Wada Y, Kowada T, Wang Z, Sun-Wada GH, Nishiyama I, Mizukami S, Maiya N, Yasuda H,
Kumanogoh A, Kikuchi K, Germain RN, Ishii M. Dynamic visualization of RANKL and Th17-mediatedosteoclast function. J Clin Invest. 123: 866-873, 2013
Koide M, Kobayashi Y, Ninomiya T, Nakamura M, Yasuda H, Arai Y, Okahashi N, Yoshinari N,
Takahashi N, Udagawa N. Osteoprotegerin-deficient male mice as a model for severe alveolar bone
loss: comparison with RANKL-overexpressing transgenic male mice. Endocrinology. 154:773-782.
2013
Miyamoto, K., Yoshida S, Kawasumi M, Hashimoto K, Kimura T, Sato Y, Kobayashi T, Miyauchi Y, Hoshi
H, Iwasaki R, Miyamoto H, Hao W, Morioka H, Chiba K, Kobayashi T, Yasuda H, Penninger JM, Toyama
Y, Suda T, Miyamoto T. Osteoclasts are dispensable for hematopoietic stem cell maintenance andmobilization., J Exp. Med., 208: 2175-2181. 2011
Furuya, Y., Mori K, Ninomiya T, Tomimori Y, Tanaka S, Takahashi N, Udagawa N, Uchida K, Yasuda H.
Increased bone mass in mice after single injection of anti-receptor activator of nuclear factorkappaB ligand-neutralizing antibody: evidence for bone anabolic effect of parathyroid hormone inmice with few osteoclasts., J Biol Chem., 286: 37023-37031, 2011 (mRANKL抗体OYC2も使用)
Soontrapa K, Honda T, Sakata D, Yao C, Hirata T, Hori S, Matsuoka T, Kita Y, Shimizu T, Kabashima K,
Narumiya S.: Prostaglandin E2-prostaglandin E receptor subtype 4 (EP4) signaling mediates UV
irradiation-induced systemic immunosuppression. Proc Natl Acad Sci U S A. 108: 6668-6673, 2011
Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin TJ,
Lindeman GJ, Visvader JE.: Control of mammary stem cell function by steroid hormone signalling.,
Nature 465: 798-802, 2010

Ver.2021

Anti-Human RANKL Monoclonal Antibody
Cat. No. 47102000
論文
Tohyama R, Kayamori K, Sato K, Hamagaki M, Sakamoto K, Yasuda H, Yamaguchi A. Establishment ofa xenograft model to explore the mechanism of bone destruction by human oral cancers and its
application to analysis of role of RANKL. J Oral Pathol Med. doi: 10.1111/jop.12376, 2015 (hRANKL中和抗体も使用)Sato K, Lee JW, Sakamoto K, Iimura T, Kayamori K, Yasuda H, Shindoh M, Ito M, Omura K, Yamaguchi
A. RANKL Synthesized by Both Stromal Cells and Cancer Cells Plays a Crucial Role in Osteoclastic
Bone Resorption Induced by Oral Cancer. Am J Pathol. 182, 1890-1899, 2013

分化誘導ペプチドW9
Cat. No. 47025000
論文
Yasuda H. Discovery of the RANKL/RANK/OPG system. J Bone Miner Metab. 39, 2-11, 2021
Nakamura M, Nakamichi Y, Koide M, Yamashita T, Ara T, Nakamura H, Penninger JM, Furuya Y,
Yasuda H, Udagawa N (2017) The W9 peptide directly stimulates osteoblast differentiation via
RANKL signaling. 59:146–151
Ozaki Y, Koide M, Furuya Y, Ninomiya T, Yasuda H, Nakamura M, Kobayashi Y, Takahashi N, Yoshinari
N, Udagawa N. Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers
alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis. PLoS One.
2017 Sep 22;12(9):e0184904. doi: 10.1371/journal.pone.0184904. eCollection 2017.
Sawa M, Wakitani S, Kamei N, Kotaka S, Adachi N, Ochi M. Local administration of WP9QY (W9)peptide promotes bone formation in a rat femur delayed-union model. J Bone Miner Metab. 2017
Jun 28. doi: 10.1007/s00774-017-0852-5. [Epub ahead of print]
Khan A, Alles N, Soysa NS, Mamun M, Nagano K, Mikami R, Furuya Y, Yasuda H, Ohya K, Aoki K. The
local administration of TNF-a and RANKL antagonist peptide promotes BMP-2inducedboneformation J Oral Biosci 55: 47–54, 2013
Furuya Y, Inagaki A, Khan M, Mori K, Penninger JM, Nakamura M, Udagawa N, Aoki K, Ohya K, Uchida
K, Yasuda H. Stimulation of bone formation in cortical bone of mice treated with a receptor
activator of nuclear factor-κB ligand (RANKL)-binding peptide that possesses osteoclastogenesis
inhibitory activity. J Biol Chem, 288: 5562-5571, 2013
Masud Khan AA, N, Soysa NS, Mamun M, Nagano K, Mikami R, Furuya Y, Yasuda H, Ohya K, Aoki K.
The local administration of TNF-a and RANKL antagonist peptide promotes BMP-2inducedboneformation. J Oral Biosci 55: 47–54, 2013
Sugamori Y, Mise-Omata S, Maeda C, Aoki S, Tabata Y, Murali R, Yasuda H, Udagawa N, Suzuki H,
Honma M, Aoki K. Peptide drugs accelerate BMP-2-induced calvarial bone regeneration andstimulate osteoblast differentiation through mTORC1 signaling. Bioessays. 2016 Jun 27. doi:
10.1002/bies.201600104.

Ver.2021